Skip to main content
High RiskFDAfda-F-1361-2023UNDECLARED ALLERGEN

belVita Breakfast Sandwich, Dark Chocolate Creme variety (6 - 21.12 oz cartons)

Units Affected
90,775
Recall Date
July 3, 2023
Issuing Agency
Hazard
Undeclared Allergen

FDA Recall Notice

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-F-1361-2023.

Mondelz Global LLC (Mondelz) has initiated a recall of various products - belVita Breakfast Sandwich Dark Chocolate Creme and belVita Breakfast Sandwich Cinnamon Brown Sugar with Vanilla Creme, because of undeclared peanut allergen due to cross contamination.

Corrective Action (per FDA)

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-F-1361-2023.

Recall terminated by FDA.

✅ What you should do

  1. Stop using the product if you own it.
  2. Check the model number, lot code, or sell-by date against the recall notice above.
  3. Contact Mondelez Global Llc or the retailer where you bought it for a refund, replacement, or repair.
  4. For the most current official instructions, visit the FDA recall page.
  5. If you've been hurt by this product, report the incident to FDA.

Consumer Contact (per FDA)

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-F-1361-2023.

Mondelez Global Llc

FDA

About the U.S. Food and Drug Administration

The FDA regulates drugs, medical devices, food, cosmetics, and tobacco. Adverse event reports and recall notices are the main public safety signal.

Visit FDA.gov →

📣 Report a food, supplement, or cosmetic problem to the FDA

If you had a reaction, found contamination, or experienced a labeling problem with this product, report it to the FDA. The agency uses consumer reports to track emerging safety signals and trigger recalls.

How to report to FDAFile a report at FDA

Mondelez Global Llc Recall FAQ

Mondelez Global Llc is the subject of a snacks & candy safety report: belVita Breakfast Sandwich, Dark Chocolate Creme variety (6 - 21.12 oz cartons). The notice was published on July 3, 2023 by the U.S. Food and Drug Administration (FDA). Approximately 90,775 units are potentially affected.